Partial
Mostly Aligned
Patient Risk:
Low
Summary
The provided claims about intrathecal-use risk and nephrogenic systemic fibrosis (NSF) are supported by the cited label sections (5.1 and 5.2). However, the overall response includes multiple product distribution/dispensing and regulatory-status claims that are not supported or assessed against the supplied FDA label excerpts, and there is no explicit evaluation of these additional claims against the label text.
Category Scores
Accurate Statements
Intrathecal administration of GBCAs can cause serious adverse reactions, and Clariscan’s safety/effectiveness are not established for intrathecal use; Clariscan is not approved for intrathecal use.
Label section 5.1 (Risk Associated with Intrathecal Use): states serious adverse reactions including death, coma, encephalopathy, seizures; safety/effectiveness not established with intrathecal use; Clariscan not approved for intrathecal use.
GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination/renal impairment.
Label section 5.2 (Nephrogenic Systemic Fibrosis): states GBCA increase in NSF risk among patients with impaired elimination; provides avoidance guidance.
NSF may result in fatal or debilitating fibrosis affecting skin, muscle, and internal organs.
Label section 5.2.
Unsupported Statements
Gadoterate meglumine is typically sold through regulated medical supply channels rather than consumer pharmacies.
No support for distribution/sales-channel statements in the provided FDA label excerpts.
Gadoterate meglumine generally requires a clinician’s prescription.
Prescription/dispensing requirement is not addressed in the provided FDA label excerpts.
Gadoterate meglumine is dispensed for a specific imaging procedure through healthcare providers.
Administration/dispensing workflow beyond intrathecal approval is not covered in the provided excerpts.
Hospitals and imaging centers may purchase gadoterate meglumine through internal procurement.
Purchasing/procurement operational details are not present in the provided label excerpts.
Licensed medical distributors may supply contrast media to healthcare providers, including gadoterate meglumine.
Distribution by distributors is not described in the provided label excerpts.
Pharmacy partners may handle prescription imaging agents for clinicians, including gadoterate meglumine.
Pharmacy partnership/handling process is not described in the provided label excerpts.
A supplier or imaging center can provide the regulatory status of gadoterate meglumine in the relevant country or region.
Regulatory-status information is not described in the provided label excerpts.
A supplier or imaging center can provide storage/handling requirements so gadoterate meglumine is supplied correctly for an imaging site.
Storage/handling requirements are not included in the provided label excerpts.
A supplier or imaging center can provide the specific product name and strength/formulation used for MRI, and package size (vials) and concentration.
Product packaging/manufacturer-supply details are not addressed in the provided label excerpts.
Contradictions
Important Omissions
No evaluation of the label’s specific NSF risk-mitigation instructions (e.g., dose not exceeding recommended dose, allowing sufficient elimination time before re-administration; hemodialysis considerations and usefulness being unknown) relative to the user’s broader claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only explicitly evaluated safety-related themes (intrathecal risk and NSF risk) are aligned with the provided label excerpts (5.1 and 5.2). Other non-safety operational/distribution claims are unsupported by the provided label text but do not themselves assert clinical harm.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims about sales/distribution, regulatory status by country, and supplier-provided storage/handling or packaging details are not supported by the provided FDA label excerpts, and were not evaluated against labeling.
Suggested Improvement
Limit the response to label-supported content from the provided prescribing information excerpts (especially Sections 5.1 and 5.2 for intrathecal and NSF risk), or provide and cite the specific label sections that address prescription/dispensing, storage/handling, and packaging/strength details.